tiprankstipranks
Accendra Health (DE:6OM)
FRANKFURT:6OM
Germany Market
6OM
Accendra Health
RESEARCH TOOLSreports

Accendra Health (6OM) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

6OM Analyst Ratings

Moderate Buy
3Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Accendra
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6OM Stock 12 Month Forecast

Average Price Target

€4.52
▲(72.35% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Accendra Health in the last 3 months. The average price target is €4.52 with a high forecast of €5.24 and a low forecast of €3.93. The average price target represents a 72.35% change from the last price of €2.62.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","2":"€2","4":"€4","6":"€6","8":"€8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5.24382018,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€5.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.515511821666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.932865135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.93</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,2.9879861676923074,3.1759723353846154,3.363958503076923,3.5519446707692306,3.7399308384615386,3.927917006153846,4.115903173846154,4.303889341538461,4.49187550923077,4.6798616769230765,4.867847844615385,5.055834012307693,{"y":5.24382018,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,2.9319624478205126,3.0639248956410254,3.1958873434615382,3.327849791282051,3.459812239102564,3.591774686923077,3.72373713474359,3.8556995825641027,3.9876620303846155,4.119624478205129,4.251586926025642,4.383549373846154,{"y":4.515511821666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,2.8871434719230766,2.974286943846154,3.0614304157692307,3.1485738876923075,3.2357173596153848,3.3228608315384616,3.4100043034615384,3.497147775384615,3.5842912473076924,3.6714347192307693,3.7585781911538465,3.8457216630769233,{"y":3.932865135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.7,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.839,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.819,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€5.24Average Price Target€4.52Lowest Price Target€3.93
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Robert W. Baird Analyst forecast on DE:6OM
Eric Coldwell
Robert W. Baird
Robert W. Baird
€4.37→€5.24
Buy
100.15%
Upside
Reiterated
05/12/26
Accendra Health price target raised to $6 from $5 at BairdAccendra Health price target raised to $6 from $5 at Baird
UBS Analyst forecast on DE:6OM
Kevin Caliendo
UBS
UBS
€2.62→€3.93
Hold
50.11%
Upside
Assigned
05/12/26
Accendra Health price target raised to $4.50 from $3 at UBSAccendra Health price target raised to $4.50 from $3 at UBS
Citi Analyst forecast on DE:6OM
Daniel Grosslight
Citi
Citi
€2.84→€4.37
Buy
66.79%
Upside
Assigned
05/12/26
Accendra Health price target raised to $5 from $3.25 at CitiAccendra Health price target raised to $5 from $3.25 at Citi
Bank of America Securities Analyst forecast on DE:6OM
Allen Lutz
Bank of America Securities
Bank of America Securities
€1.97
Sell
-24.95%
Downside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (NASDAQ: DMAC), Xtant Medical Holdings (NYSE MKT: XTNT) and Accendra Health (NYSE: ACH)
Leerink Partners Analyst forecast on DE:6OM
Michael Cherny
Leerink Partners
Leerink Partners
€4.37→€5.24
Hold
100.15%
Upside
Assigned
10/09/25
Owens & Minor (OMI) Gets a Hold from Leerink Partners
J.P. Morgan Analyst forecast on DE:6OM
Lisa Gill
J.P. Morgan
J.P. Morgan
€6.12→€5.24
Sell
100.15%
Upside
Reiterated
08/27/25
Owens & Minor price target lowered to $6 from $7 at JPMorganOwens & Minor price target lowered to $6 from $7 at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Robert W. Baird Analyst forecast on DE:6OM
Eric Coldwell
Robert W. Baird
Robert W. Baird
€4.37→€5.24
Buy
100.15%
Upside
Reiterated
05/12/26
Accendra Health price target raised to $6 from $5 at BairdAccendra Health price target raised to $6 from $5 at Baird
UBS Analyst forecast on DE:6OM
Kevin Caliendo
UBS
UBS
€2.62→€3.93
Hold
50.11%
Upside
Assigned
05/12/26
Accendra Health price target raised to $4.50 from $3 at UBSAccendra Health price target raised to $4.50 from $3 at UBS
Citi Analyst forecast on DE:6OM
Daniel Grosslight
Citi
Citi
€2.84→€4.37
Buy
66.79%
Upside
Assigned
05/12/26
Accendra Health price target raised to $5 from $3.25 at CitiAccendra Health price target raised to $5 from $3.25 at Citi
Bank of America Securities Analyst forecast on DE:6OM
Allen Lutz
Bank of America Securities
Bank of America Securities
€1.97
Sell
-24.95%
Downside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (NASDAQ: DMAC), Xtant Medical Holdings (NYSE MKT: XTNT) and Accendra Health (NYSE: ACH)
Leerink Partners Analyst forecast on DE:6OM
Michael Cherny
Leerink Partners
Leerink Partners
€4.37→€5.24
Hold
100.15%
Upside
Assigned
10/09/25
Owens & Minor (OMI) Gets a Hold from Leerink Partners
J.P. Morgan Analyst forecast on DE:6OM
Lisa Gill
J.P. Morgan
J.P. Morgan
€6.12→€5.24
Sell
100.15%
Upside
Reiterated
08/27/25
Owens & Minor price target lowered to $6 from $7 at JPMorganOwens & Minor price target lowered to $6 from $7 at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OCGNOcugen
ASNDAscendis Pharma
CRBPCorbus Pharmaceuticals
ARDXArdelyx
MGTXMeiragtx Holdings
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Accendra Health

3 Months
Allen LutzBank of America Securities
Success Rate
10/15 ratings generated profit
67%
Average Return
+9.70%
Copying Allen Lutz's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +9.70% per trade.
1 Year
Allen LutzBank of America Securities
Success Rate
12/15 ratings generated profit
80%
Average Return
+29.72%
Copying Allen Lutz's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +29.72% per trade.
2 Years
Allen LutzBank of America Securities
Success Rate
12/15 ratings generated profit
80%
Average Return
+39.99%
Copying Allen Lutz's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +39.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6OM Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
1
0
2
2
2
Buy
1
1
0
0
0
Hold
1
1
1
1
1
Sell
3
2
1
0
0
Strong Sell
0
0
0
0
0
total
6
4
4
3
3
In the current month, 6OM has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 6OM average Analyst price target in the past 3 months is 4.52.
Each month's total comprises the sum of three months' worth of ratings.

6OM Financial Forecast

6OM Earnings Forecast

Next quarter’s earnings estimate for 6OM is -€0.07 with a range of -€0.15 to <€0.01. The previous quarter’s EPS was -€0.04. 6OM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 6OM has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6OM is -€0.07 with a range of -€0.15 to <€0.01. The previous quarter’s EPS was -€0.04. 6OM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 6OM has Performed in-line its overall industry.

6OM Sales Forecast

Next quarter’s sales forecast for 6OM is €550.78M with a range of €535.94M to €557.05M. The previous quarter’s sales results were €549.94M. 6OM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 6OM has Performed in-line its overall industry.
Next quarter’s sales forecast for 6OM is €550.78M with a range of €535.94M to €557.05M. The previous quarter’s sales results were €549.94M. 6OM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 6OM has Performed in-line its overall industry.

6OM Stock Forecast FAQ

What is DE:6OM’s average 12-month price target, according to analysts?
Based on analyst ratings, Accendra Health’s 12-month average price target is 4.52.
    What is DE:6OM’s upside potential, based on the analysts’ average price target?
    Accendra Health has 72.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Accendra Health a Buy, Sell or Hold?
          Accendra Health has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Accendra Health’s share price target?
            The average share price target for Accendra Health is 4.52. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €5.24 ,and the lowest forecast is €3.93. The average share price target represents 72.35% Increase from the current price of €2.62.
              What do analysts say about Accendra Health?
              Accendra Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Accendra Health?
                To buy shares of DE:6OM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.